Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation
(2007) In Ugeskrift for Laeger 169(5). p.420-423- Abstract
- Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.
- Abstract (Swedish)
- Abstract in Danish
Infliximab er effektiv ved reumatoid artritis (RA), men behandlingssvigt er hyppige. Sera fra 106 RA-patienter monitoreredes med en radioimmunoassay (RIA) for funktionel infliximab og en RIA for anti-infliximab-antistof. S-infliximab varierede betydeligt, f.eks. 0-22 μg/ml forud for tredje infusion, og efter seks måneder var 44% antistofpositive. Lav S-infliximab var forbundet med antistofudvikling og senere terapisvigt, og høje antistofniveauer kunne relateres til dosisøgning, bivirkninger og terapiophør. Farmakologisk monitorering kan formentlig optimere behandlinger med anti-tumornekrose-antistof.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1138514
- author
- Bendtzen, Klaus ; Geborek, Pierre LU ; Svenson, Morten ; Larsson, Lotta ; Kapetanovic, Meliha C and Saxne, Tore LU
- organization
- alternative title
- Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Ugeskrift for Laeger
- volume
- 169
- issue
- 5
- pages
- 420 - 423
- publisher
- Den Almindelige Danske Lægeforening
- external identifiers
-
- pmid:17280636
- scopus:33846922580
- ISSN
- 0041-5782
- language
- Danish
- LU publication?
- yes
- id
- dbd70585-c136-47c1-b75a-184b69ddf7dd (old id 1138514)
- alternative location
- http://www.ugeskriftet.dk/LF/UFL/2007/5/pdf/VP51189.pdf
- date added to LUP
- 2016-04-01 15:47:46
- date last changed
- 2022-03-22 06:17:06
@article{dbd70585-c136-47c1-b75a-184b69ddf7dd, abstract = {{Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.}}, author = {{Bendtzen, Klaus and Geborek, Pierre and Svenson, Morten and Larsson, Lotta and Kapetanovic, Meliha C and Saxne, Tore}}, issn = {{0041-5782}}, language = {{dan}}, number = {{5}}, pages = {{420--423}}, publisher = {{Den Almindelige Danske Lægeforening}}, series = {{Ugeskrift for Laeger}}, title = {{Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation}}, url = {{http://www.ugeskriftet.dk/LF/UFL/2007/5/pdf/VP51189.pdf}}, volume = {{169}}, year = {{2007}}, }